The potential sale of its 88% stake in Bausch + Lomb could generate billions for creditors and shareholders of the indebted ...

It was quite a busy and eventful day for the company.

Bausch Health has recently changed its strategy for Bausch + Lomb, looking to sell the segment which has a market capitalization of nearly $8 billion. The potential sale of Bausch + Lomb is a break ...

Bullish option flow detected in Bausch Health (BHC) with 5,026 calls trading, 2x expected, and implied vol increasing over 2 ...

Key Takeaways Bausch + Lomb shares surged Monday following reports Blackstone and TPG are considering teaming up to buy the ...

Bausch & Lomb (NYSE:BLCO) jumped 9% in premarket trading on a report that private equity firms TPG (TPG) and Blackstone (BX) ...

Evercore ISI upgraded shares of Bausch Health Companies (TSE:BHC – Free Report) to a hold rating in a research note published ...

Bausch Health faces $21 billion in debt, with $10 billion due by 2027 and a $2.4 billion loan due next year. Private equity ...

On Oct. 4, The Paso Robles Daily News first broke the story, “Paso Robles city manager files complaint against city ...

Evercore ISI upgraded shares of Bausch + Lomb (NYSE:BLCO – Free Report) from an in-line rating to an outperform rating in a ...

VAUGHAN, Ontario, October 14, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better ...

The FDA granted approval to the enVista Envy full range of vision IOLs following Canadian approval in May 2024.